Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired stem cell disorder marked by complement-mediated intravascular hemolysis. It arises from somatic mutations in the PIGA gene, leading to loss of glycosylphosphatidylinositol (GPI)-anchored proteins that normally protect red cells from complement attack. Without these proteins, red blood cells become highly vulnerable to lysis, leading to chronic hemolysis and systemic complications.

Though uncommon, PNH is clinically significant due to its chronicity, life-threatening risks such as thrombosis, and its long-term effect on quality of life. The advent of complement inhibitors has shifted PNH from a historically fatal disease to a manageable chronic condition. Still, optimal care requires ongoing monitoring, individualised therapy, and attention to both medical and psychosocial needs.⁴

This review highlights long-term management strategies that reduce morbidity and mortality while improving daily functioning and quality of life for patients with PNH.

Understanding the clinical course and complications of PNH

The natural history of PNH is shaped by three main processes: intravascular hemolysis, thrombosis, and bone marrow failure.

• Hemolysis and anaemia. Chronic hemolysis is the hallmark of PNH, presenting with fatigue, dark urine, and dyspnea. Many patients develop anaemia requiring transfusion support, while ongoing hemolysis can trigger complications such as nitric oxide depletion, smooth muscle dystonia, and oesophageal spasm^1,4
• Thrombosis. Thrombosis remains the leading cause of mortality, often occurring in unusual venous sites such as hepatic, mesenteric, or cerebral veins. The interplay of complement activation, platelet dysfunction, and hemolysis drives this risk. Complement inhibitors have greatly reduced thrombotic mortality, but vigilance remains essential²
• Bone marrow failure. PNH frequently overlaps with aplastic anaemia or myelodysplastic syndromes, reflecting shared stem cell dysfunction. This adds cytopenias beyond hemolysis, complicating management⁴
• Long-term risks. Recurrent hemoglobinuria can cause chronic kidney disease through hemosiderin deposition. Pulmonary hypertension may develop due to nitric oxide depletion. Patients are also vulnerable to infections from both marrow dysfunction and complement blockade⁴
• The role of monitoring. Early diagnosis has improved with flow cytometry, detecting even small PNH clones. However, diagnosis is only the beginning. Continuous monitoring of hemolysis, thrombosis risk, renal and pulmonary status, and marrow function is critical. Regular follow-up and patient education on warning signs form the backbone of safe long-term care⁴

Disease-modifying therapies and advances in treatment

Complement inhibition: the therapeutic backbone

Terminal complement inhibition transformed PNH care. Eculizumab, the first C5 inhibitor, changed the disease from fatal to chronic, reducing hemolysis, transfusions, and thrombosis while improving survival. Long-term studies confirm sustained benefits with ongoing therapy.^2,4

Ravulizumab, a longer-acting derivative of eculizumab, provides equivalent efficacy with less frequent dosing, easing treatment burden. Together, these C5 inhibitors are the current standard of care.²

Expanding therapeutic options

Recent advances have broadened treatment. Proximal complement inhibitors like pegcetacoplan target C3, preventing both intravascular and extravascular hemolysis and improving anaemia in patients with residual disease on C5 blockade. Trials show superiority of pegcetacoplan over eculizumab in selected endpoints.²

Next-generation agents, including subcutaneous anti-C5 drugs such as crovalimab, provide more convenient dosing and maintain effective control. These innovations expand patient choice, particularly for those prioritising reduced treatment frequency.⁴

Benefits and remaining challenges

Complement inhibitors reduce hemolysis, transfusions, and thrombosis, the major drivers of morbidity. Yet challenges remain: lifelong therapy, high costs, global disparities in access, and occasional breakthrough or extravascular hemolysis requiring regimen changes.^2,4

Hematopoietic stem cell transplantation (HSCT)

Allogeneic HSCT remains the only curative approach, replacing the abnormal clone entirely. It is considered for patients with severe marrow failure, refractory disease, or when transplant benefits outweigh risks. Despite improving outcomes, HSCT carries risks of mortality and graft-versus-host disease, so it is reserved for carefully selected patients at experienced centres.⁵

Supportive and Preventive Care in Long-Term Management

Transfusion practice and iron management

Red-cell transfusion remains an important supportive therapy for symptomatic anaemia or during acute hemolytic crises. With the advent of complement inhibitors, many patients have reduced transfusion needs, but iron overload can still develop in those with chronic transfusion exposure and should be monitored with ferritin and, when indicated, MRI-based liver/ cardiac iron quantification. Timely initiation of chelation therapy is important for long-term organ protection.⁴

Anticoagulation for thrombosis prevention and treatment

Thrombosis is the major life-threatening complication of PNH. Established venous or arterial thrombosis mandates therapeutic anticoagulation. In patients with prior thrombotic events, complement inhibition reduces recurrence risk but does not eliminate it entirely; individualised decisions about chronic prophylactic anticoagulation should weigh bleeding risks, residual hemolysis, and patient comorbidities, ideally in coordination with haematology and thrombosis specialists. Historical and contemporary data support the dramatic impact of complement blockade in lowering thrombotic complications.^2,4

Vaccination and infection prevention on complement blockers

Terminal complement inhibition increases susceptibility to encapsulated organisms, especially Neisseria meningitidis. Vaccination against meningococcal serogroups (MenACWY and MenB), ideally completed before initiating therapy, is universally recommended; despite vaccination, the risk is not eliminated, so clinicians should counsel patients about fever/sepsis symptoms and consider prophylactic antibiotics per local guidance. Clinical and public-health authorities provide detailed vaccination and monitoring guidance for patients receiving complement inhibitors.⁴

Lifestyle modifications and symptom management

Simple, practical measures improve day-to-day function. Adequate hydration, sleep hygiene, graded physical activity, and nutrition help mitigate fatigue and improve functional capacity. Patients benefit from tailored plans for work/ school adjustments during symptomatic periods, and from psychosocial support to manage chronic disease burden. Education about signs of hemolysis, thrombosis, and infection empowers patients to seek prompt care.^1,4

Practical approach: integrating disease-modifying and supportive care

• Confirm diagnosis and risk stratify (clone size, hemolytic markers, thrombosis history, marrow status)
• Offer complement inhibition to patients with clinically significant hemolysis, thrombosis, or transfusion dependence, selecting agents based on efficacy, dosing preference, comorbidities, and access^2,4
• Provide vaccinations and infection counselling before or at therapy initiation and maintain vigilance for invasive infections
• Manage complications through anticoagulating when indicated, monitor renal and pulmonary sequelae, treat anaemia and iron overload, and refer for HSCT evaluation when appropriate⁵
• Address quality of life through symptom control, rehabilitation, psychosocial support, and patient education³

Enhancing Quality of Life and Psychosocial Well-Being

Living with PNH extends beyond laboratory markers. Daily fatigue, pain, anxiety about thrombosis or infection, and the practical demands of ongoing therapy shape identity, relationships, and career paths. Addressing these dimensions is central to comprehensive care.^1,4

• Fatigue and pain. Fatigue is the most common and disabling symptom. Management includes correcting reversible causes such as uncontrolled hemolysis or iron deficiency, and then using graded exercise, sleep optimisation, and occupational or physical therapy. Complement inhibition often improves fatigue, but many patients need additional supportive interventions^1,4
• Mental health support. PNH brings psychological strain: uncertainty about prognosis, fear of complications, and stress from frequent medical visits. Screening for anxiety and depression should be routine, with easy access to counselling or peer mentoring. Addressing mental health improves treatment adherence and overall quality of life^1,4
• Patient education and peer networks. Knowledge empowers patients. Education about hemolytic flares, thrombotic symptoms, infection risks, and what to do if therapy is interrupted reduces anxiety and prevents delays. Peer groups provide shared experience, practical advice, and emotional support, reducing isolation^1,4
• Adherence and access. Long-acting drugs such as ravulizumab reduce treatment burden, but adherence depends on cost, access, and psychosocial support. Real-world data show higher persistence with extended-interval regimens.³ Social work, case management, and financial counselling are critical for maintaining continuity
• Impact on work and family. PNH often forces lifestyle adjustments like reduced work hours, career changes, and altered family responsibilities. Clinicians should address employment capacity, provide documentation for workplace accommodations, and involve vocational rehabilitation when needed. Family-inclusive education reduces strain and enhances support networks¹

Clinic-level actions to improve quality of life

• Screen regularly for fatigue, pain, anxiety, and depression
• Offer multidisciplinary care: physiotherapy, occupational therapy, pain services, and psychology
• Prioritise education and connect patients with advocacy groups
• Anticipate access barriers with financial and logistical support, and set protocols for missed doses^3,4

FAQs

Who can develop paroxysmal nocturnal hemoglobinuria (PNH)?

PNH is a rare condition that can affect adults of any age. It arises from an acquired genetic change in blood-forming stem cells, rather than being inherited. While uncommon, anyone with unexplained anaemia, fatigue, or unusual blood clots may need evaluation for PNH.

How is PNH treated in the long term?

The mainstay of therapy is complement inhibition with drugs like eculizumab or ravulizumab, which reduce hemolysis and thrombosis. Newer agents, such as pegcetacoplan and crovalimab, are expanding treatment options. In rare cases, stem cell transplantation is considered for curative intent.

Why is supportive care important for PNH patients?

Even with disease-modifying therapies, patients may need blood transfusions, iron monitoring, anticoagulation for clot prevention, and vaccinations to reduce infection risks. Supportive care ensures safety, prevents complications, and improves day-to-day well-being.

How does PNH affect quality of life?

Beyond physical symptoms like fatigue and pain, PNH impacts mental health, work capacity, and family life. Counselling, patient education, and access to peer support groups play a vital role in helping patients manage the emotional and social aspects of living with a chronic condition.

Summary

Long-term success in PNH is no longer measured solely by survival but by sustained control of hemolysis, prevention of thrombosis and critically the patient’s ability to live well. Achieving that requires an integrated approach: potent disease-modifying therapies to control the biology of PNH, vigilant supportive care (transfusion, anticoagulation, vaccination, renal and cardiopulmonary surveillance), and proactive attention to psychosocial needs, employment and daily function.^1,4

The therapeutic landscape is expanding: proximal complement inhibitors, longer-acting C5 agents, and improvements in delivery all promise better control, fewer visits and potential gains in quality of life.^2,4 But medicine alone is not enough; equitable access, durable adherence supports, and holistic, multidisciplinary care are required to translate scientific advances into meaningful life improvements for people with PNH. With coordinated care and attention to the human side of disease, many patients can expect longer, more productive, and more fulfilling lives.^3,5